Kabra Drugs Limited (BOM:524322)

Kabra Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	71.66	-	-	-	-	-
Cost of Revenue	67.5	-	-	-	-	-
Gross Profit	4.16	-	-	-	-	-
Selling, General & Admin	9.65	7.55	4.55	2.64	1.2	0.7
Other Operating Expenses	11.21	9.63	2.82	0.81	0.55	0.78
Operating Expenses	20.96	17.25	7.36	3.44	1.84	1.79
Operating Income	-16.8	-17.25	-7.36	-3.44	-1.84	-1.79
Interest & Investment Income	-	-	-	0.06	-	-
Other Non Operating Income (Expenses)	6.4	6.4	-	-	-	-
EBT Excluding Unusual Items	-10.39	-10.85	-7.36	-3.38	-1.84	-1.79
Gain (Loss) on Sale of Investments	-	-	-	-	-0.01	-0.01
Pretax Income	-10.39	-10.85	-7.36	-3.38	-1.85	-1.8
Income Tax Expense	0.01	0.01	-	-	-	-
Net Income	-10.4	-10.86	-7.36	-3.38	-1.85	-1.8
Net Income to Common	-10.4	-10.86	-7.36	-3.38	-1.85	-1.8
Shares Outstanding (Basic)	16	11	4	4	4	4
Shares Outstanding (Diluted)	16	11	4	4	4	4
Shares Change (YoY)	260.13%	149.01%	-	-	-	-
EPS (Basic)	-0.66	-0.99	-1.68	-0.77	-0.42	-0.41
EPS (Diluted)	-0.66	-0.99	-1.68	-0.77	-0.42	-0.41
Free Cash Flow	-	-47.58	-2.09	-3.54	-1.34	-2.49
Free Cash Flow Per Share	-	-4.35	-0.47	-0.81	-0.30	-0.57
Gross Margin	5.81%	-	-	-	-	-
Operating Margin	-23.44%	-	-	-	-	-
Profit Margin	-14.51%	-	-	-	-	-
EBITDA	-	-17.18	-	-3.34	-1.74	-1.48
D&A For EBITDA	-	0.07	-	0.1	0.1	0.31
EBIT	-16.8	-17.25	-7.36	-3.44	-1.84	-1.79
EBIT Margin	-23.44%	-	-	-	-	-
Revenue as Reported	78.06	6.4	-	0.06	-	-
Advertising Expenses	-	0.17	0.19	0.09	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.